Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12610546 | 0.88 | DRD4 (0.60) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL5666675 | 0.85 | DRD4 (0.63) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL4316173 | 0.84 | DRD4 (0.66) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL8482318 | 0.81 | DRD4 (0.62) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL4638143 | 0.81 | L3MBTL1 (0.54) | DRD4SIGMAR1 | |
| SCHEMBL8482312 | 0.81 | DRD4 (0.62) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL4638141 | 0.81 | L3MBTL1 (0.54) | DRD4SIGMAR1 | |
| SCHEMBL2904781 | 0.81 | L3MBTL1 (0.54) | DRD4SIGMAR1 | |
| SCHEMBL6203552 | 0.81 | DRD4 (0.61) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL2228313 | 0.80 | DRD4 (0.71) | DRD4DRD2DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747236-A1 | PIPERIDINE, MORPHOLINE AND TETRAHYDRO-PYRIDAZINE COMPOUNDS WITH LP(A) LOWERING ACTIVITY | Eli Lilly and Company (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2025024210-A1 | PIPERIDINE, MORPHOLINE AND TETRAHYDRO-PYRIDAZINE COMPOUNDS WITH LP(A) LOWERING ACTIVITY | ELI LILLY AND COMPANY (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4121422-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-111377917-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2012120476-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120476-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| EP-0398426-B1 | Antirhinoviral (thio)morpholinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA NV (BE) | 1994-03-09 | — | — | EP | disclosed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-5070090-A | SUSTAINED RELEASE FROM CYCLODEXTRIN INCLUSION COMPOUND | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-12-03 | — | — | US | disclosed |
| EP-0398426-A1 | Antirhinoviral (thio)morpholinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| US-4889857-A | BACTERICIDES; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0311948-A2 | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | DRD4 3776/4885SIGMAR1 3941/4885DRD2 2785/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | DRD4 3776/4885SIGMAR1 3941/4885DRD2 2785/4885 |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | DRD4 1753/4885SIGMAR1 722/4885DRD2 2112/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | DRD4 1753/4885SIGMAR1 722/4885DRD2 2112/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | DRD4 1753/4885SIGMAR1 722/4885DRD2 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.